HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Finance In Brief

This article was originally published in The Rose Sheet

Executive Summary

LVMH: Company's perfumes and cosmetics business grew 9% on a reported basis during the first three quarters of FY 2007 to $2.79 bil., according to Oct. 15 earnings release from Moet Hennessy Louis Vuitton. The division's performance was particularly strong in Europe and Asia owing to a strong launch of the Christian Dior scent Midnight Poison and solid results from other new fragrances including TokyobyKenzo, Palazzo, a new release from Fendi and the Pucci scent Vivara. The "rapid progress" of cosmetics brand Benefit also contributed, LVMH says. The firm's selective retailing unit booked $4.1 bil. for the period, with Sephora continuing "to win market share in Europe and in the U.S. and to expand its business in the Middle East and China." Overall, LVMH achieved sales of $16.2 bil. for the first three quarters of FY 2007...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015027

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel